GeneReach Biotechnology Cash Flow Conversion Efficiency
GeneReach Biotechnology cash flow conversion efficiency. Based on the latest financial reports, GeneReach Biotechnology (4171) has a cash flow conversion efficiency ratio of 0.011x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$6.28 Million ≈ $197.92K USD) by net assets (NT$581.48 Million ≈ $18.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GeneReach Biotechnology (2017–2025)
Cash flow conversion efficiency of GeneReach Biotechnology from 2017 to 2025. This chart illustrates how GeneReach Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 4171 stock price for real-time trading data and today's change.
GeneReach Biotechnology Cash Flow Conversion Ratio Explained
GeneReach Biotechnology cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GeneReach Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneReach Biotechnology ranked by their cash flow conversion efficiency. Also see market value of GeneReach Biotechnology for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pharmx Technologies Ltd
AU:PHX
|
-0.559x |
|
Plus500 Ltd
LSE:PLUS
|
0.247x |
|
Archer Materials Ltd
AU:AXE
|
-0.246x |
|
Uvre Ltd
AU:UVA
|
-0.248x |
|
Wave Electronics Co. Ltd
KQ:095270
|
-0.010x |
|
Ideal Power Inc
NASDAQ:IPWR
|
-0.274x |
|
DGR Global Ltd
AU:DGR
|
-0.049x |
|
Latrobe Magnesium Ltd
AU:LMG
|
0.060x |
Annual Cash Flow Conversion Efficiency for GeneReach Biotechnology (2017–2025)
The table below shows the annual cash flow conversion efficiency of GeneReach Biotechnology from 2017 to 2025. Review 4171 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$596.72 Million ≈ $18.80 Million |
NT$-13.52 Million ≈ $-425.80K |
-0.023x | +29.25% |
| 2024-12-31 | NT$725.49 Million ≈ $22.86 Million |
NT$-23.22 Million ≈ $-731.68K |
-0.032x | +28.61% |
| 2023-12-31 | NT$862.44 Million ≈ $27.17 Million |
NT$-38.67 Million ≈ $-1.22 Million |
-0.045x | -113.83% |
| 2022-12-31 | NT$1.10 Billion ≈ $34.74 Million |
NT$357.63 Million ≈ $11.27 Million |
0.324x | +1.12% |
| 2021-12-31 | NT$1.09 Billion ≈ $34.28 Million |
NT$348.99 Million ≈ $11.00 Million |
0.321x | +62.01% |
| 2020-12-31 | NT$857.76 Million ≈ $27.02 Million |
NT$169.82 Million ≈ $5.35 Million |
0.198x | +1148.98% |
| 2019-12-31 | NT$593.05 Million ≈ $18.68 Million |
NT$-11.19 Million ≈ $-352.64K |
-0.019x | -202.24% |
| 2018-12-31 | NT$311.15 Million ≈ $9.80 Million |
NT$5.74 Million ≈ $180.97K |
0.018x | +167.78% |
| 2017-12-31 | NT$250.63 Million ≈ $7.90 Million |
NT$-6.83 Million ≈ $-215.06K |
-0.027x | -- |
About GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assa… Read more